Self-collection does not mean screening without care
Patient-collected high-risk HPV testing may help reach people who avoid or cannot access clinician collection. In 2026, ACOG included this approach as an option for selected average-risk patients. The change is important, but it applies to validated kits and to a health system capable of delivering results and follow-up.
The safe message is not “a home test replaces medical care.” Self-collection changes who takes the sample. It does not remove the need for clinical oversight, genotype-informed triage or further examination after a positive result.
What does ACOG recommend in the United States?
For average-risk patients aged 30–65 years, clinician-collected primary hrHPV testing every five years is preferred. Patient-collected primary hrHPV every three years may be considered when the patient prefers this method and when approved kits, documentation, notification and follow-up are available.
The three-year interval matters. ACOG states that evidence supporting a five-year interval after self-collection is not yet available.
For ages 21–29, cytology every three years remains the recommended approach in the ACOG statement. Individuals with previous high-grade lesions or cervical cancer, HIV or other important immunosuppression, in-utero DES exposure, or those under surveillance after abnormal results require an individual pathway.
What does a positive hrHPV result mean?
A positive result does not mean cervical cancer. It means that a carcinogenic HPV type was detected. Management depends on the genotype, available triage tests and the person’s screening history. Some results lead to repeat testing, while others require cytology, dual-stain testing or colposcopy according to the local guideline.
Before using a self-collection kit, ask who will communicate the result and arrange the next step. A test without a reliable follow-up pathway can create delay rather than prevention.
Why should US guidance not be copied directly to Poland?
Screening programmes are jurisdiction-specific. Age ranges, approved assays, sampling methods, reimbursement and follow-up differ. The Polish national pathway must therefore be checked on current NFZ and Pacjent.gov.pl pages at the time of publication.
The 2026 JAMA Network Open analysis on the growing never-screened population supports the need to improve reach. It did not test self-collection itself and should not be presented as proof that self-collection solved the screening gap.
Three questions before testing
- Is this assay and collection device validated for patient collection?
- Who will interpret and communicate the result?
- Is this an average-risk screening situation or do I need individual surveillance?
Conclusion
Validated HPV self-collection can make screening more accessible. Its clinical value depends on the entire pathway: correct eligibility, a validated test, result notification and timely follow-up. The US guidance is a useful implementation example, not a replacement for the current Polish programme.
Sources: ACOG Committee Statement No. 28, Screening for Cervical Cancer (2026); JAMA Network Open, DOI: https://doi.org/10.1001/jamanetworkopen.2026.31550; current NFZ and Pacjent.gov.pl cervical-screening information.
Editorial note: educational material; it does not replace individual medical advice or surveillance after an abnormal result.